Thus, in conditions of high systemic CRP, there may be a greater likelihood of tumor cells undergoing an ‘immunologically silent’ death with minimal antigen presentation to facilitate priming and activation of effector T cells and may contribute to the lack of efficacy of a PD-L1 blockade. The gene discussed is CRP; the disease is neoplasm.